Skip to main content
Finanzoo GmbHFinanzoo GmbH

Array BioPharma Value Stock - Dividend - Research Selection

Array biopharma

ISIN: US04269X1054 , WKN: 580564

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company\'s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


Solar Stocks Rally After Presidential Debate: Should Investors Give Chase?

2024-09-15
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
TalkMarkets

What do rate cuts, the election mean for solar energy stocks?

2024-09-13
Mizuho Americas director of clean energy equity research Maheep Manley joins Julie Hyman and Josh Lipton on Market Domination to discuss what next week's expected interest rate cut and the upcoming presidential election mean for the solar energy sector. “There's a nice transition from interest rates to solar,” Manley says explaining that “we've seen this industry react to any positive news on interest rates” and “we'll continue to see that going forward.” The analyst tells Yahoo Finance that most companies in the solar industry have a high debt-to-capital ratio, so there’s “a lot of upside there” if the Federal Reserve does in fact opt to cut rates. Solar companies “generally tend to do better in a lower interest rate environment,” he adds. Solar stocks came into focus after the presidential debate on Tuesday. A victory for Vice President Kamala Harris in November could “keep the status quo of the Inflation Reduction Act,” which includes tax incentives for clean energy. The analyst highlights that First Solar is “the biggest beneficiary” of current tax incentives as “more than 60% of their EPS in our estimates for 2025 would come from these incentives from the Inflation Reduction Act (IRA). Manley adds, “I don't think it'll be very bad news if Republicans or Trump come on in,” with “at worst” a 20% or 25% impact on solar stocks. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Naomi Buchanan.
Yahoo

Solar Stocks Rally After Presidential Debate: Should Investors Chase?

2024-09-13
Solar stocks have seen quite a rebound this week following Tuesday's presidential debate in which democratic nominee Kamala Harris emphasized building out alternative energy assets.
Yahoo

Is Array Technologies (ARRY) the Cheapest Clean Energy Stock to Buy According to Hedge Funds?

2024-09-13
We recently compiled a list of the 10 Cheap Clean Energy Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Array Technologies (NASDAQ:ARRY) stands against the other cheap clean energy stocks. The Clean Energy Market is Booming According to a report by the International Energy Agency […]
Yahoo

Why Array Technologies, Inc. (ARRY) Outpaced the Stock Market Today

2024-09-12
In the latest trading session, Array Technologies, Inc. (ARRY) closed at $6.68, marking a +1.21% move from the previous day.
Yahoo

Did Array Technologies, Inc. (NASDAQ:ARRY) Use Debt To Deliver Its ROE Of 12%?

2024-09-11
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Yahoo

Solar stocks trading higher following last night's presidential debate

2024-09-11
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Seeking Alpha

Array Technologies launches reusable packaging solution

2024-09-11
The new reusable bulk packaging comes with a life cycle of up to 15 years.
Yahoo

ARRAY Technologies Introduces Reusable Packaging Option

2024-09-10
The Company launches reusable plastic packaging to enhance sustainability and reduce costsALBUQUERQUE, N.M., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a global leader in utility-scale solar tracking, today announced the launch of a groundbreaking reusable packaging solution designed to replace traditional cardboard boxes with durable, reusable plastic casing. This innovative packaging is set to significantly reduce waste and contribute to th
Yahoo

Marathon Capital Hires James Fitzgerald as Head of Institutional Sales

2024-09-10
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Business Wire